EUCTR2021-000014-42-BE进行中（未招募）1 期
A randomized, double-blind, placebo-controlled, parallel, trial to determine the safety and efficacy of inhaled AQ001S in the management of acute COVID-19 symptoms - SIROCCO 1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient admitted to hospital due to the severity of his/her confirmed or suspected COVID-19 disease.
- •2. Positive virus test for SARS-CoV-2 using RT-PCR (nasal swab).
- •3. Patient with COVID-19 clinical progression scale score = 4 (hospitalized; no oxygen therapy).
- •4. Male or female, =18 years of age at the time of consent.
- •5. Patients who have given written informed consent.
- •6. Reliable patients who are willing to be available for the duration of the clinical trial and willing to comply with clinical trial procedures.
- •7. Patients who have the ability to understand the requirements of the clinical trial.
- •8. Female patients of childbearing potential (women of childbearing potential, WOCBP) should have a negative pregnancy test at Screening Visit.
- •9. Female patients of childbearing potential (women of childbearing potential, WOCBP) using a highly effective method of contraception (i.e., pregnancy rate of < 1% per year) on a stable regimen, for at least 28 days, and pursuing this contraception during the trial and for 28 days after the last administration of the IMP. The highly effective methods of contraception must be one of the following: combined estrogen and progestogen hormonal contraception with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or agreement on continuous abstinence from heterosexual intercourse.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 49
排除标准
- •1. Intensive care patients
- •2. Inability to use a nebulizer with a mouthpiece.
- •3. History of hypersensitivity to corticosteroid or to any of the excipients in the drug preparation.
- •4. Untreated oral candidiasis.
- •5. Evidence of symptomatic chronic or acute respiratory infection other than COVID-19 in the previous 8 weeks.
- •6. Proven diagnosis of asthma or bronchiectasis.
- •7. Proven diagnosis of COPD treated with ongoing ICS and/or corticosteroid treatment within 3 months prior to randomization.
- •8. Pulmonary malformations, tuberculosis, cystic fibrosis.
- •9. History or presence of severe hepatic impairment (i.e. alanine transaminase (ALT) and aspartate transaminase (AST) greater than 15 times the upper limit of normal)
- •10. History or presence of severe renal impairment (considered as clinically significant according to the investigator’s discretion (i.e., stage 4 (DFR=15-29 mL/min)).
- •11. Anticipated transfer to another hospital within 72 hours.
- •12. Use of ICS, at a strength at least equivalent to 200 µg of beclomethasone per day, within 7 days before Screening Visit.
- •13. Female patients who are breast-feeding, lactating, pregnant or intending to become pregnant.
- •14. Any condition, including findings in the patients' medical history or in the pre-randomization study assessments that, in the opinion of the Investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation.
- •15. Current or previous participation in another clinical trial where the patient has received a dose of an IMP containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-FRsanofi-aventis recherche & développement550
进行中（未招募）
不适用
A study to determine the appropriate dose(s) of Dupilumab (REGN668)in adult patients with moderate to severe atopic dermatitis (eczema)Atopic dermatitsMedDRA version: 16.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2012-003651-11-PLRegeneron Pharmaceuticals, Inc.240
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-ATsanofi-aventis recherche & développement550
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-ESMenarini International Operations Luxembourg SA538
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.Rheumatoid ArthritisEUCTR2004-005210-37-DEF. Hoffmann La-Roche AG1,200